Augmont Enterprises Limited reports Q2 FY27 results and approves ESOP plan

Augmont Enterprises Limited has announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported a profit of ₹1,203.03 million for the quarter, a significant increase from the previous year. Key approvals from the Board of Directors include the appointment of Secretarial Auditors and the ratification of its pre-IPO ESOP plan, subject to shareholder approval.

Financial Highlights for Q2 FY27

Augmont Enterprises Limited disclosed its unaudited financial results for the second quarter and first half of the fiscal year ending September 30, 2026. For the quarter ended September 30, 2026, the company reported a profit of ₹1,203.03 million. This figure is part of the total comprehensive income of ₹1,203.75 million for the same period. The consolidated figures for the half-year ended September 30, 2026, show a profit of ₹1,811.55 million and total comprehensive income of ₹1,814.77 million.

Key Board Approvals

The Board of Directors, in its meeting held on November 4, 2026, approved several key items. These include the unaudited financial results, the statement indicating the utilization of public issue proceeds, and the appointment of M/s. Sanjay Dholakia and Associates as Secretarial Auditors for a five-year term starting from FY 2026-27. Additionally, the Board recommended revised monetary limits for loans and investments, approved entering into material related party transactions, and recommended for shareholder approval, the ratification of the pre-IPO Augmont Enterprises Limited ESOP Plan – 2025.

Other Approvals and Disclosures

The Board also approved extending the ESOP plan to include eligible employees of the company’s subsidiary companies. The financial results, along with the limited review reports from the statutory auditors, have been enclosed as Annexure-1. The utilization of public issue proceeds is detailed in Annexure-2.

Source: BSE

Previous Article

Aurobindo Pharma declares 700% interim dividend of Rs 7 per share

Next Article

Balkrishna Industries Ltd. outlines growth roadmap and FY27 highlights